Comparative Xenograft Models Across Tumor Types: Breast, Colorectal, Pancreatic, Glioblastoma

April 1, 2026

Introduction Xenograft models are versatile platforms for investigating diverse cancer types, each presenting unique challenges in tumor biology, therapeutic targeting, and translational predictivity. Comparative analyses across tumor types highlight how

Mechanisms of Therapy Resistance in Xenografts: Epigenetic and Microenvironmental Drivers

March 1, 2026

Introduction One of the most pressing challenges in oncology is the emergence of therapy resistance. Even when initial responses are robust, tumors frequently recur in more aggressive, treatment-refractory forms. Xenograft

Applications of PDX in Co-Clinical Trials and Personalized Medicine Workflows

February 1, 2026

Introduction Patient-Derived Xenografts (PDX) have redefined translational oncology by directly linking preclinical research to clinical decision-making. Beyond their role in drug discovery, PDX models are increasingly employed in co-clinical trials,

Quality Control, Genetic Drift, and Reproducibility Challenges in Long-Term Xenograft Studies

January 1, 2026

Introduction Xenograft models have transformed preclinical oncology by providing in vivo systems that retain many biological and molecular features of human tumors. Yet, long-term use of these models introduces significant

Humanized Xenograft Models: Immune-Relevant Systems

December 1, 2025

Introduction Traditional xenograft models provide valuable insights into tumor biology and therapeutic efficacy but are fundamentally limited in their ability to evaluate immunotherapies. Since immunodeficient murine hosts lack functional adaptive

Modeling Intratumoral Heterogeneity and Clonal Evolution Using PDX Systems

November 1, 2025

Introduction Intratumoral heterogeneity is a defining feature of human cancers and a primary driver of therapeutic resistance. Conventional in vitro models fail to capture the dynamic interplay between co-existing subclones,

Patient-Derived Xenografts (PDX): Foundations & Workflow

October 1, 2025

Introduction Patient-Derived Xenografts (PDX) represent one of the most translationally relevant in vivo cancer models available to preclinical research. By directly implanting tumor fragments harvested from patients into immunodeficient mice,

Fundamentals of Xenograft Models in Preclinical Oncology

September 1, 2025

Introduction Xenograft models are indispensable tools in oncology research, providing a physiologically relevant in vivo platform to study tumor biology, evaluate therapeutic responses, and bridge the translational gap between preclinical

The XMD Project xenograft.org: A Centralized Resource for Preclinical In Vivo Cancer Models

August 1, 2025

Plymouth Meeting, PA – August 2025 – Cancer remains one of the greatest health burdens worldwide. Preclinical models are indispensable for developing therapies that can effectively translate from the laboratory